Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis

References

• Risau W. Mechanisms of angiogenesis. Nature 1997; 386:671–4; PMID:9109485; http://dx.doi.org/10.1038/386671a0
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31; PMID:7584949; http://dx.doi.org/10.1038/nm0195-27
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:932-6; PMID:16355210; http://dx.doi.org/10.1038/nature04478.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438:967-74; PMID:16355214; http://dx.doi.org/10.1038/nature04483.
   PubMed Web of Science ®Google Scholar
• Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature 2005; 438:937-45; PMID:16355211; http://dx.doi.org/10.1038/nature04479.
   PubMed Web of Science ®Google Scholar
• Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12:303-24; PMID:8281615; http://dx.doi.org/10.1007/BF00665960.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76; PMID:12778165; http://dx.doi.org/10.1038/nm0603-669.
   PubMed Web of Science ®Google Scholar
• Kolch W, Martiny-Baron G, Kieser A, Marme D. Regulation of the expression of the VEGFVPS and its receptors: role in tumor angiogenesis. Breast Cancer Res Treat 1995; 36:139-55; PMID:8534863; http://dx.doi.org/10.1007/BF00666036.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298-307; PMID:21593862; http://dx.doi.org/10.1038/nature10144.
   PubMed Web of Science ®Google Scholar
• Sato Y, Kanno S, Oda N, Abe M, Ito M, Shitara K, Shibuya M. Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann N Y Acad Sci 2000; 902:201-5; discussion 5-7; PMID:10865839; http://dx.doi.org/10.1111/j.1749-6632.2000.tb06314.x.
   PubMed Web of Science ®Google Scholar
• Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985; 228:1049-55; PMID:3887571; http://dx.doi.org/10.1126/science.3887571.
   PubMed Web of Science ®Google Scholar
• Gordi T, Lepist EI. Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol Lett 2004; 147:99-107; PMID:14757313; http://dx.doi.org/10.1016/j.toxlet.2003.12.009.
   PubMed Web of Science ®Google Scholar
• Tu Y. The development of new antimalarial drugs: qinghaosu and dihydro-qinghaosu. Chin Med J (Engl) 1999; 112:976-7; PMID:11721477.
   PubMed Web of Science ®Google Scholar
• Crespo-Ortiz MP, Wei MQ. Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol 2012; 2012:247597; PMID:22174561; http://dx.doi.org/10.1155/2012/247597.
   PubMed Web of Science ®Google Scholar
• Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol 2001; 18:767-73; PMID:11251172.
   PubMed Web of Science ®Google Scholar
• Dell’Eva R, Pfeffer U, Vene R, Anfosso L, Forlani A, Albini A, Efferth T. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol 2004; 68:2359-66; http://dx.doi.org/10.1016/j.bcp.2004.08.021.
   PubMed Web of Science ®Google Scholar
• Zhang CZ, Zhang H, Yun J, Chen GG, Lai PB. Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol 2012; 83:1278-89; PMID:22342732; http://dx.doi.org/10.1016/j.bcp.2012.02.002.
   PubMed Web of Science ®Google Scholar
• Zhou HJ, Zhang JL, Li A, Wang Z, Lou XE. Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro. Cancer Chemother Pharmacol 2010; 66:21-9; PMID:19756601; http://dx.doi.org/10.1007/s00280-009-1129-z.
   PubMed Web of Science ®Google Scholar
• Lu JJ, Meng LH, Shankavaram UT, Zhu CH, Tong LJ, Chen G, Lin LP, Weinstein JN, Ding J. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol 2010; 80:22-30; PMID:20206143; http://dx.doi.org/10.1016/j.bcp.2010.02.016.
   PubMed Web of Science ®Google Scholar
• Longo M, Zanoncelli S, Torre PD, Riflettuto M, Cocco F, Pesenti M, Giusti A, Colombo P, Brughera M, Mazue G, et al. In vivo and in vitro investigations of the effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos. Reprod Toxicol 2006; 22:797-810; PMID:16959470; http://dx.doi.org/10.1016/j.reprotox.2006.08.001.
   PubMed Web of Science ®Google Scholar
• Chen HH, Zhou HJ, Wang WQ, Wu GD. Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother Pharmacol 2004; 53:423-32; PMID:15132130; http://dx.doi.org/10.1007/s00280-003-0751-4.
   PubMed Web of Science ®Google Scholar
• Chen HH, Zhou HJ, Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res 2003; 48:231-6; PMID:12860439; http://dx.doi.org/10.1016/S1043-6618(03)00107-5.
   PubMed Web of Science ®Google Scholar
• Wu GD, Zhou HJ, Wu XH. Apoptosis of human umbilical vein endothelial cells induced by artesunate. Vascular Pharmacol 2004; 41:205-12; PMID:15653096; http://dx.doi.org/10.1016/j.vph.2004.11.001.
   PubMed Web of Science ®Google Scholar
• D’Alessandro S, Basilico N, Corbett Y, Scaccabarozzi D, Omodeo-Sale F, Saresella M, Marventano I, Vaillant M, Olliaro P, Taramelli D. Hypoxia modulates the effect of dihydroartemisinin on endothelial cells. Biochem Pharmacol 2011; 82:476-84; http://dx.doi.org/10.1016/j.bcp.2011.06.002.
   PubMed Web of Science ®Google Scholar
• Zhou HJ, Wang WQ, Wu GD, Lee J, Li A. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascular Pharmacol 2007; 47:131-8; PMID:17581794; http://dx.doi.org/10.1016/j.vph.2007.05.002.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Sun B, Cheng ZX, Zhou HX, Gao Y, Kong R, Chen H, Jiang HC, Pan SH, Xue DB, et al. Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-kappaB pathway. Cancer Chemother Pharmacol 2011; 68:1421-30; PMID:21479633; http://dx.doi.org/10.1007/s00280-011-1643-7.
   PubMed Web of Science ®Google Scholar
• Terman BI, Dougher-Vermazen M. Biological properties of VEGFVPF receptors. Cancer Metastasis Rev 1996; 15:159-63; PMID:8842487; http://dx.doi.org/10.1007/BF00437468.
   PubMed Web of Science ®Google Scholar
• Ronicke V, Risau W, Breier G. Characterization of the endothelium-specific murine vascular endothelial growth factor receptor-2 (Flk-1) promoter. Circ Res 1996; 79:277-85; PMID:8756005; http://dx.doi.org/10.1161/01.RES.79.2.277.
   PubMed Web of Science ®Google Scholar
• Huxford T, Huang DB, Malek S, Ghosh G. The crystal structure of the IkappaBalphaNF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell 1998; 95:759-70; PMID:9865694; http://dx.doi.org/10.1016/S0092-8674(00)81699-2.
   PubMed Web of Science ®Google Scholar
• Jacobs MD, Harrison SC. Structure of an IkappaBalphaNF-kappaB complex. Cell 1998; 95:749-58; PMID:9865693; http://dx.doi.org/10.1016/S0092-8674(00)81698-0.
   PubMed Web of Science ®Google Scholar
• Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB. Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene 2007; 26:7324-32; PMID:17533369; http://dx.doi.org/10.1038/sj.onc.1210544.
   PubMed Web of Science ®Google Scholar
• Haussler U, von Wichert G, Schmid RM, Keller F, Schneider G. Epidermal growth factor activates nuclear factor-kappaB in human proximal tubule cells. Am J Physiol Renal Physiol 2005; 289:F808-15; PMID:15798085; http://dx.doi.org/10.1152/ajprenal.00434.2003.
   PubMed Web of Science ®Google Scholar
• Patterson C, Perrella MA, Hsieh CM, Yoshizumi M, Lee ME, Haber E. Cloning and functional analysis of the promoter for KDRflk-1, a receptor for vascular endothelial growth factor. J Biol Chem 1995; 270:23111-8; PMID:7559454; http://dx.doi.org/10.1074/jbc.270.39.23111.
   PubMed Web of Science ®Google Scholar
• Minami T, Rosenberg RD, Aird WC. Transforming growth factor-beta 1-mediated inhibition of the flk-1KDR gene is mediated by a 5’-untranslated region palindromic GATA site. J Biol Chem 2001; 276:5395-402; PMID:11098056; http://dx.doi.org/10.1074/jbc.M008798200.
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock HW, Sternsdorf T, Liese J, Belohradsky B, Weber C, Wedel A, Schreck R, Bauerle P, Strobel M. Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes. J Immunol 1993; 151:6986-93; PMID:8258705.
   PubMed Web of Science ®Google Scholar
• Liu SF, Ye X, Malik AB. Pyrrolidine dithiocarbamate prevents I-kappaB degradation and reduces microvascular injury induced by lipopolysaccharide in multiple organs. Mol Pharmacol 1999; 55:658-67; PMID:10101023.
   PubMed Web of Science ®Google Scholar
• Yoshida A, Yoshida S, Ishibashi T, Kuwano M, Inomata H. Suppression of retinal neovascularization by the NF-kappaB inhibitor pyrrolidine dithiocarbamate in mice. Invest Ophthalmol Vis Sci 1999; 40:1624-9; PMID:10359349.
   PubMed Web of Science ®Google Scholar
• Ho WE, Peh HY, Chan TK, Wong WS. Artemisinins: Pharmacological actions beyond anti-malarial. Pharmacol Ther 2013; PMID:24316259.
   PubMed Web of Science ®Google Scholar
• Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12:895-904; PMID:16892035; http://dx.doi.org/10.1038/nm1469.
   PubMed Web of Science ®Google Scholar
• Yamaguchi TP, Dumont DJ, Conlon RA, Breitman ML, Rossant J. flk-1, an flt-related receptor tyrosine kinase is an early marker for endothelial cell precursors. Development 1993; 118:489-98; PMID:8223275.
   PubMed Web of Science ®Google Scholar
• DeBusk LM, Massion PP, Lin PC. IkappaB kinase-alpha regulates endothelial cell motility and tumor angiogenesis. Cancer Res 2008; 68:10223-8; PMID:19074890; http://dx.doi.org/10.1158/0008-5472.CAN-08-1833.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Maeda S, Hikiba Y, Nakagawa H, Hayakawa Y, Shibata W, Yanai A, Ogura K, Omata M. Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res: An Off J Am AssocCancer Res 2009; 15:2248-58; PMID:19276252; http://dx.doi.org/10.1158/1078-0432.CCR-08-1383.
   PubMed Web of Science ®Google Scholar
• Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS, Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001; 276:22382-7; PMID:11297551; http://dx.doi.org/10.1074/jbc.M100938200.
   PubMed Web of Science ®Google Scholar
• Calzado MA, Bacher S, Schmitz ML. NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Curr Med Chem 2007; 14:367-76; PMID:17305539; http://dx.doi.org/10.2174/092986707779941113.
   PubMed Web of Science ®Google Scholar
• Brouard S, Berberat PO, Tobiasch E, Seldon MP, Bach FH, Soares MP. Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-kappa B to protect endothelial cells from tumor necrosis factor-alpha-mediated apoptosis. J Biol Chem 2002; 277:17950-61; PMID:11880364; http://dx.doi.org/10.1074/jbc.M108317200.
   PubMed Web of Science ®Google Scholar
• Martin D, Galisteo R, Gutkind JS. CXCL8IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3Bcl10Malt1) complex. J Biol Chem 2009; 284:6038-42; PMID:19112107; http://dx.doi.org/10.1074/jbc.C800207200.
   PubMed Web of Science ®Google Scholar
• Wang J, Guo Y, Zhang BC, Chen ZT, Gao JF. Induction of apoptosis and inhibition of cell migration and tube-like formation by dihydroartemisinin in murine lymphatic endothelial cells. Pharmacology 2007; 80:207-18; PMID:17622766; http://dx.doi.org/10.1159/000104418.
   PubMed Web of Science ®Google Scholar
• Zhong YY, Zhang HF, Zhong JX, Bai L, Lu XH. Topical dihydroartemisinin inhibits suture-induced neovascularization in rat corneas through ERK12 and p38 pathways. Int J Ophthalmol 2011; 4:150-5; PMID:22553631.
   PubMed Web of Science ®Google Scholar
• Gariano RF. Special features of human retinal angiogenesis. Eye (Lond) 2010; 24:401-7; PMID:20075971; http://dx.doi.org/10.1038/eye.2009.324.
   PubMed Web of Science ®Google Scholar
• Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res 2010; 29:500-19; PMID:20488255; http://dx.doi.org/10.1016/j.preteyeres.2010.05.003.
   PubMed Web of Science ®Google Scholar